Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.
COVID-19
MERS
SARS
guideline
lopinavir
recommendation
ritonavir
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
30 Jun 2020
30 Jun 2020
Historique:
received:
21
05
2020
revised:
17
06
2020
accepted:
22
06
2020
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
8
7
2020
Statut:
epublish
Résumé
A life-threatening respiratory illness (COVID-19) due to severe acute respiratory syndrome (SARS)-CoV-2 coronavirus was first described in December 2019 in Wuhan (China), rapidly evolving into a pandemic. In the first phase, when the viral replication plays a pivotal pathogenetic role, antiviral drugs could be crucial in limiting viral-induced organ damage. Unfortunately, there are no specific antivirals of proven efficacy for COVID-19, and several drugs have been repurposed to face this dramatic pandemic. In this paper we review the studies evaluating lopinavir/ritonavir association (LPV/r) use in COVID-19, and previously in SARS and Middle East respiratory syndrome (MERS). We searched PubMed to identify all relevant clinical and laboratory studies published up to 15 May 2020; the guidelines on the use of LPV/r in COVID-19 were further directly searched on the website of the main international scientific societies and agencies. Available evidence is currently scarce and of low quality. The recommendations issued for COVID-19 vary from positions clearly against the use of LPV/r to other positions that are more favorable. In our opinion, despite the controversial results of an important randomized clinical trial, and some recommendations, clinicians should not abandon the use of LPV/r for the treatment of COVID-19, possibly using this drug inside a prospective randomized trial, waiting for the results of the numerous ongoing trials evaluating its efficacy.
Identifiants
pubmed: 32629768
pii: jcm9072050
doi: 10.3390/jcm9072050
pmc: PMC7408758
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
Infect Chemother. 2020 Jun;52(2):281-304
pubmed: 32342676
CMAJ. 2020 May 19;192(20):E536-E545
pubmed: 32350002
Science. 2020 Mar 27;367(6485):1412-1413
pubmed: 32217705
Yonsei Med J. 2020 May;61(5):431-437
pubmed: 32390367
Br J Hosp Med (Lond). 2020 Apr 2;81(4):1-2
pubmed: 32339007
N Engl J Med. 2020 May 21;382(21):e68
pubmed: 32369284
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Mil Med Res. 2020 Feb 6;7(1):4
pubmed: 32029004
Crit Care Med. 2020 Jun;48(6):e440-e469
pubmed: 32224769
Hong Kong Med J. 2003 Dec;9(6):399-406
pubmed: 14660806
Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3390-3396
pubmed: 32271456
N Engl J Med. 2020 May 21;382(21):e68
pubmed: 32369285
Antiviral Res. 2020 Jun;178:104786
pubmed: 32251767
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
J Infect Dis. 2015 Dec 15;212(12):1904-13
pubmed: 26198719
J Infect. 2020 Jul;81(1):e21-e23
pubmed: 32283143
PLoS Med. 2006 Sep;3(9):e343
pubmed: 16968120
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
Trials. 2018 Jan 30;19(1):81
pubmed: 29382391
J Infect. 2020 Jul;81(1):e1-e5
pubmed: 32171872
Arch Acad Emerg Med. 2020 Apr 06;8(1):e45
pubmed: 32309809
N Engl J Med. 2020 May 21;382(21):e68
pubmed: 32369286
Biosci Trends. 2020 Mar 16;14(1):69-71
pubmed: 31996494
Clin Infect Dis. 2020 Nov 19;71(16):2199-2206
pubmed: 32407459
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7
pubmed: 15226499
Infect Chemother. 2016 Jun;48(2):118-26
pubmed: 27433382
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
J Korean Med Sci. 2020 Feb 17;35(6):e79
pubmed: 32056407
J Antimicrob Chemother. 2020 Sep 1;75(9):2704-2706
pubmed: 32407513
J Microbiol Immunol Infect. 2020 Jun;53(3):488-492
pubmed: 32331982
J Med Virol. 2020 Jun;92(6):556-563
pubmed: 32104907
J Int AIDS Soc. 2020 Apr;23(4):e25489
pubmed: 32293807
Biochemistry. 2020 May 12;59(18):1769-1779
pubmed: 32293875
J Crit Care. 2020 Aug;58:29-33
pubmed: 32330817
Curr Med Chem. 2020;27(27):4536-4541
pubmed: 32297571
Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84
pubmed: 24841269
J Chem Inf Model. 2020 Jun 22;60(6):3277-3286
pubmed: 32315171
Pharmacol Res. 2020 Jul;157:104872
pubmed: 32360583
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Clin Microbiol Infect. 2020 Jul;26(7):880-894
pubmed: 32360444